COVID 19 Impact modeling

COVID  19 has become a prime disruptor in the operating model for the commercialization cycle of biopharmaceutical brands. What used to be a cycle plan driven operating environment, is now rapidly transforming into an always on, HCP led, data driven operating model.

We have experience working closely with the world’s foremost experts including the Gates foundation, Johns Hopkins University, Imperial College and Google and building techniques to incorporate exogenous factors into our models.

We have built scenarios based on a range of probabilistic outcomes to accurately estimate the impact of COVID 19 aftermath on market forecasts, market-mix modeling, return on investments based on channel type, change in patient behavior, access to services, tele-health, disease awareness and impact on patient support programs.


Close Menu